← SynDRA
RIGOSERTIB
SynDRA canonical compound SYN0024473 — structure-anchored drug synonym record
| Clinical phase | Phase 3 |
|---|
| Primary target(s) | MCL1 | PLK1 |
|---|
| Mechanism of action | cell cycle inhibitor | PLK inhibitor |
|---|
All known targets
Mechanisms of action (all sources)
- cell cycle inhibitor
- PLK inhibitor
- PLK1 MODULATOR
- PIK3CG MODULATOR
Bioactivity evidence (ChEMBL activities table — not curator-asserted)
- NQO2
- CLK3
- FECH
- MET
- AAK1
- PAK4
- PDGFRB
- PCYT1A
- PASK
- PAK6
- PAK2
- PFKP
- PAICS
- OPA1
- OLA1
- NUAK2
- NTRK1
- NLK
- PDXK
- PHKG2
- NEK7
- PIM1
- PRKAR2A
- PRKAG2
- PRKAG1
- PRKACG
- PRKACB
- PRKACA
- PRKAA1
- PLK4
- PKN3
- PKN2
- PKN1
- PKMYT1
- PIP4K2C
- PIP4K2A
- PIM2
- NEK9
- NEK3
- PRKCB
Drug classes
- Antineoplastic Agents
- Protein Kinase Inhibitors
Cross-references
Synonyms
- ON-01910
- ON01910
- UNII-67DOW7F9GL
- 67DOW7F9GL
- N-[2-Methoxy-5-({[(E)-2-(2,4,6-Trimethoxyphenyl)ethenyl]sulfonyl}methyl)phenyl]glycine
- ON-01910.Na
- Rigosertib [USAN:INN]
- 6FS
- Rigosertib (USAN)
- AC1OCFT5
- SCHEMBL498624
- Estybon (proposed trade name)
- SCHEMBL498623
- GTPL7833
- CHEMBL1241855
- ON01910.Na
- DTXSID30207984
- CHEBI:124939
- OWBFCJROIKNMGD-BQYQJAHWSA-N
- 1910 Na
- ZINC3942646
- BCP08296
- BDBM50060917
- 4006AH
- AKOS015966442
- DB12146
- SB16468
- (E)-2-((2-methoxy-5-(((2,4,6-trimethoxystyryl)sulfonyl)methyl)phenyl)amino)acetic a
- ON 01910
- Rigosertib [USAN]
- 2-[2-methoxy-5-[[(E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonylmethyl]anilino]acetic acid
- (E)-2-((2-methoxy-5-(((2,4,6-trimethoxystyryl)sulfonyl)methyl)phenyl)amino)acetic acid
- N-[2-Methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]glycine
- rigosertibum
- N-[2-Methoxy-5-({[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl}methyl)phenyl]glycine
- RIGOSERTIB [INN]
- RIGOSERTIB [WHO-DD]
- 2-[2-methoxy-5-[2-(2,4,6-trimethoxyphenyl)ethenylsulfonylmethyl]anilino]acetic acid
- CHEBI:145417
Look up RIGOSERTIB in the interactive SynDRA portal →